Warning: UK E-liquids may Contain Dangerous Synthetic Drugs

Regulations by 2FIRSTS.ai
Feb.08.2024
Warning: UK E-liquids may Contain Dangerous Synthetic Drugs
Warning: Some e-liquids sold in the UK may contain illicit substances, including synthetic cannabinoids known as "spice."

Recently, health experts in Wales, UK issued a warning claiming that e-liquids being sold in the country may contain synthetic marijuana compounds known as "Spice". They argue that these illicit e-liquids have extremely potent medicinal effects and pose a danger to users who opt for counterfeit prescription drug e-cigarette products.

 

Some e-liquids consumed by UK consumers in their daily lives contain cannabis, CBD, or tetrahydrocannabinol (THC). Recently, WEDINOS, the only nationwide drug testing service in the UK, conducted tests and found that certain e-liquids being sold in the market also contain a potent synthetic drug known as synthetic cannabinoid receptor agonists (SCRAs), sometimes referred to as "spice." Based on these test results, the Welsh public health department has stated that some of these products being sold in the UK pose significant risks to consumers.

 

Synthetic cannabinoid receptor agonists (SCRAs) are a group of compounds associated with significant health issues, ranging from respiratory difficulties to psychiatric episodes. The latest data from WEDINOS, an organization, reveals that out of the 196 liquid samples submitted to them in 2023, 75 samples (almost one-third) contained one or more SCRA compounds.

 

These samples were purchased in the form of cannabis, CBD, or THC e-liquids. Among the number of hospitalizations due to illicit drugs, opioids are the most prevalent, followed by cannabis and synthetic cannabinoids such as Spice. Opioids also remain the most likely type of drug to be associated with drug-related deaths.

 

Experts from the agency have expressed concern over a significant increase in the number of counterfeit prescription drug samples they have received, which have been contaminated with potentially hazardous substances. They have also frequently detected the presence of benzodiazepines, a class of drugs commonly purchased as prescription medication, such as diazepam and hydrocodone.

 

These highly concentrated synthetic opioid medications can pose a threat to life, and there is a significant risk of overdosing. Last year, WEDINOS received 90 samples containing nitrous nitrogen drugs, with nearly 50% purchased under the mistaken belief of being an anti-anxiety medication called diazepam.

 

Professor Rick Lines, the Head of Drug Abuse at the Welsh Public Health Department, has highlighted the need to recognize the increased risk of medication overdose associated with high-concentration drugs. "Our concern is that people who purchase e-cigarettes online may not actually be receiving what they believe they are getting," he cautioned.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | BAT Japan Launches virto Bright Peach Click in Japan, Expanding glo Hilo’s Capsule-Based Flavor Portfolio
Product | BAT Japan Launches virto Bright Peach Click in Japan, Expanding glo Hilo’s Capsule-Based Flavor Portfolio
British American Tobacco Japan (BAT Japan) has introduced virto Bright Peach Click, a new heated tobacco stick designed for the glo Hilo system. The product expands the existing virto consumable lineup with a combination of tobacco, menthol and ripe peach flavors, featuring a capsule mechanism that releases additional fruit flavor when activated. The product launched in Japan on July 27, 2026, through glo official online channels, convenience stores and tobacco retailers.
Aug.03
From Nicotine Pouches to Soft Candy Forms: China Tobacco Hubei explores adjustable-release oral nicotine products
From Nicotine Pouches to Soft Candy Forms: China Tobacco Hubei explores adjustable-release oral nicotine products
China-based China Tobacco Hubei Industrial Co., Ltd. has filed a patent application covering an oral nicotine product and its preparation method. The patent proposes a soft candy-shaped oral nicotine product containing nicotine ingredients, gelling agents, sweeteners and alkaline pH regulators. Through formulation adjustments and homogeneous or dual-layer structures, the technology aims to achieve different nicotine release profiles. The filing reflects exploration of new oral nicotine product formats and controlled nicotine delivery approaches.
Aug.06
Nasdaq-Listed Vape Company iSpire Technology Restructures Leadership as Tuanfang Liu Becomes Sole CEO, BTIG Initiates Coverage on ODM Growth Opportunity
Nasdaq-Listed Vape Company iSpire Technology Restructures Leadership as Tuanfang Liu Becomes Sole CEO, BTIG Initiates Coverage on ODM Growth Opportunity
Nasdaq-listed vape company iSpire Technology has restructured its leadership team, with Tuanfang Liu becoming the company’s sole chief executive officer (CEO) and Michael Wang appointed CEO of Aspire North America. The move ends iSpire’s previous co-CEO structure and creates clearer responsibilities between group strategy and regional execution. Separately, BTIG initiated coverage on iSpire Technology with a Buy rating and a $3.50 price target, identifying ODM growth opportunities as a key investment factor.
Jul.27
Product | Summo 150K Introduces Refillable Design With Up to 150,000 Puffs, Exploring a New High-Capacity Vape Format
Product | Summo 150K Introduces Refillable Design With Up to 150,000 Puffs, Exploring a New High-Capacity Vape Format
Summo has introduced the Summo 150K Refillable Disposable Vape, entering the ultra-high-puff vape segment with a claimed capacity of up to 150,000 puffs. The device combines a 40ml dual e-liquid system, transparent tank design, dual mesh coils and a 900mAh rechargeable battery, using a refillable structure to differentiate itself from conventional disposable vapes. The product appeared on overseas online retail channels including Vapesourcing and VapeBarTime between late June and early July 2026.
Jul.22
Global Tobacco Control Faces Regional Adaptation Test as Nicotine Markets Evolve, Asian Specialist Says
Global Tobacco Control Faces Regional Adaptation Test as Nicotine Markets Evolve, Asian Specialist Says
As e-cigarettes, heated tobacco products and nicotine pouches expand across global markets, a central question is gaining urgency: can tobacco control rely on a universal policy model? In an interview with 2Firsts, Asian public health and addiction medicine specialist Dr. Rashidi Mohamed bin Pakri Mohamed says Western experience remains relevant, but policies must be adapted to local culture, healthcare systems, enforcement capacity, illicit markets and clinical evidence.
Jul.08
BREAKING | China’s Tobacco Regulator Summons iMiracle Over Suspected Compliance Breaches
BREAKING | China’s Tobacco Regulator Summons iMiracle Over Suspected Compliance Breaches
Based on public records reviewed by 2Firsts, this is the first time China’s State Tobacco Monopoly Administration has publicly announced regulatory talks with an e-cigarette company.
Jul.29